Esperoct

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Download Risalah maklumat (PIL)
20-11-2023
Download Ciri produk (SPC)
20-11-2023
Download Laporan Penilaian Awam (PAR)
21-09-2023

Bahan aktif:

Turoctocog alfa pegol

Boleh didapati daripada:

Novo Nordisk A/S

Kod ATC:

B02BD02

INN (Nama Antarabangsa):

turoctocog alfa pegol

Kumpulan terapeutik:

Antihemorrhagics

Kawasan terapeutik:

Hemophilia A

Tanda-tanda terapeutik:

Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia A (congenital factor VIII deficiency).

Ringkasan produk:

Revision: 6

Status kebenaran:

Authorised

Tarikh kebenaran:

2019-06-20

Risalah maklumat

                                49
B. PACKAGE LEAFLET
50
PACKAGE LEAFLET: INFORMATION FOR THE USER
ESPEROCT 500 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
ESPEROCT 1
000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
ESPEROCT 1
500 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
ESPEROCT 2
000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
ESPEROCT 3
000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
ESPEROCT 4
000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
ESPEROCT 5
000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
turoctocog alfa pegol (pegylated human coagulation factor VIII (rDNA))
This medicine is subject to additional monitoring. This will allow
quick identification of new
safety information. You can help by reporting any side effects you may
get. See the end of section 4
for how to report side effects.
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
–
Keep this leaflet. You may need to read it again.
–
If you have any further questions, ask your doctor.
–
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
–
If you get any side effects, talk to your doctor. This includes any
possible side effects not listed
in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Esperoct is and what it is used for
2.
What you need to know before you use Esperoct
3.
How to use Esperoct
4.
Possible side effects
5.
How to store Esperoct
6.
Contents of the pack and other information
1.
WHAT ESPEROCT
IS AND WHAT IT IS USED FOR
WHAT ESPEROCT IS
Esperoct contains the active substance turoctocog alfa pegol and is a
long-acting recombinant
coagulation factor VIII product. Factor VIII is a protein found in the
blood that helps to prevent and
stop bleeding.
WHAT ESPEROCT IS USED FOR
Esperoct is used to treat and prevent bleeding in people 12 years and
above with haemophilia A
(inborn factor VIII deficiency).
In people with haemophilia A, factor VIII is missi
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
This medicinal product is subject to additional monitoring. This will
allow quick identification of
new safety information. Healthcare professionals are asked to report
any suspected adverse reactions.
See section 4.8 for how to report adverse reactions.
1.
NAME OF THE MEDICINAL PRODUCT
Esperoct 500 IU powder and solvent for solution for injection
Esperoct 1 000 IU powder and solvent for solution for injection
Esperoct 1 500 IU powder and solvent for solution for injection
Esperoct 2 000 IU powder and solvent for solution for injection
Esperoct 3 000 IU powder and solvent for solution for injection
Esperoct 4 000 IU powder and solvent for solution for injection
Esperoct 5 000 IU powder and solvent for solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Esperoct 500 I
U powder and solvent for solution for injection
Each powder vial contains nominally 500 IU turoctocog alfa pegol*.
After reconstitution, 1 mL of solution contains approximately 125 IU
turoctocog alfa pegol.
Esperoct 1 000 IU powder and solvent for solution for injection
Each powder vial contains nominally 1 000 IU turoctocog alfa pegol*.
After reconstitution, 1 mL of solution contains approximately 250 IU
turoctocog alfa pegol.
Esperoct 1 500 IU powder and solvent for solution for injection
Each powder vial contains nominally 1 500 IU turoctocog alfa pegol*.
After reconstitution, 1 mL of solution contains approximately 375 IU
turoctocog alfa pegol.
Esperoct 2 0
00 IU powder and solvent for solution for injection
Each powder vial contains nominally 2 000 IU turoctocog alfa pegol*.
After reconstitution, 1 mL of solution contains approximately 500 IU
turoctocog alfa pegol.
Esperoct 3 0
00 IU powder and solvent for solution for injection
Each powder vial contains nominally 3 000 IU turoctocog alfa pegol*.
After reconstitution, 1 mL of solution contains approximately 750 IU
turoctocog alfa pegol.
Esperoct 4 000 IU powder and solvent for solution for injection
Each powder vial contains nominally
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 20-11-2023
Ciri produk Ciri produk Bulgaria 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 21-09-2023
Risalah maklumat Risalah maklumat Sepanyol 20-11-2023
Ciri produk Ciri produk Sepanyol 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 21-09-2023
Risalah maklumat Risalah maklumat Czech 20-11-2023
Ciri produk Ciri produk Czech 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Czech 21-09-2023
Risalah maklumat Risalah maklumat Denmark 20-11-2023
Ciri produk Ciri produk Denmark 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 21-09-2023
Risalah maklumat Risalah maklumat Jerman 20-11-2023
Ciri produk Ciri produk Jerman 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 21-09-2023
Risalah maklumat Risalah maklumat Estonia 20-11-2023
Ciri produk Ciri produk Estonia 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 21-09-2023
Risalah maklumat Risalah maklumat Greek 20-11-2023
Ciri produk Ciri produk Greek 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Greek 21-09-2023
Risalah maklumat Risalah maklumat Perancis 20-11-2023
Ciri produk Ciri produk Perancis 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 21-09-2023
Risalah maklumat Risalah maklumat Itali 20-11-2023
Ciri produk Ciri produk Itali 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Itali 21-09-2023
Risalah maklumat Risalah maklumat Latvia 20-11-2023
Ciri produk Ciri produk Latvia 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 21-09-2023
Risalah maklumat Risalah maklumat Lithuania 20-11-2023
Ciri produk Ciri produk Lithuania 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 21-09-2023
Risalah maklumat Risalah maklumat Hungary 20-11-2023
Ciri produk Ciri produk Hungary 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 21-09-2023
Risalah maklumat Risalah maklumat Malta 20-11-2023
Ciri produk Ciri produk Malta 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Malta 21-09-2023
Risalah maklumat Risalah maklumat Belanda 20-11-2023
Ciri produk Ciri produk Belanda 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 21-09-2023
Risalah maklumat Risalah maklumat Poland 20-11-2023
Ciri produk Ciri produk Poland 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Poland 21-09-2023
Risalah maklumat Risalah maklumat Portugis 20-11-2023
Ciri produk Ciri produk Portugis 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 21-09-2023
Risalah maklumat Risalah maklumat Romania 20-11-2023
Ciri produk Ciri produk Romania 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Romania 21-09-2023
Risalah maklumat Risalah maklumat Slovak 20-11-2023
Ciri produk Ciri produk Slovak 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 21-09-2023
Risalah maklumat Risalah maklumat Slovenia 20-11-2023
Ciri produk Ciri produk Slovenia 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 21-09-2023
Risalah maklumat Risalah maklumat Finland 20-11-2023
Ciri produk Ciri produk Finland 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Finland 21-09-2023
Risalah maklumat Risalah maklumat Sweden 20-11-2023
Ciri produk Ciri produk Sweden 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 21-09-2023
Risalah maklumat Risalah maklumat Norway 20-11-2023
Ciri produk Ciri produk Norway 20-11-2023
Risalah maklumat Risalah maklumat Iceland 20-11-2023
Ciri produk Ciri produk Iceland 20-11-2023
Risalah maklumat Risalah maklumat Croat 20-11-2023
Ciri produk Ciri produk Croat 20-11-2023
Laporan Penilaian Awam Laporan Penilaian Awam Croat 21-09-2023

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen